反応式
[CH3:1][C:2]1[CH:3]=[CH:4][C:5]([C:12]2C=N[N:15]([CH3:17])[CH:16]=2)=[C:6]([CH:11]=1)[C:7]([O:9][CH3:10])=[O:8].CC1C=CC(B2OC(C)(C)C(C)(C)O2)=C(C=1)C(OC)=O.I[C:39]1C=NC=C[N:40]=1>>[CH3:1][C:2]1[CH:3]=[CH:4][C:5]([C:12]2[CH:16]=[N:15][CH:17]=[CH:39][N:40]=2)=[C:6]([CH:11]=1)[C:7]([O:9][CH3:10])=[O:8]参加物
4
実験手順
The title compound was synthesized following the same general protocol as described for methyl 5-methyl-2-(1-methyl-1H-pyrazol-4-yl)benzoate in Example A1, using methyl 5-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate and using 2-iodopyrazine. ESI-MS (m/z): 229 [M+1]+.
出典と根拠
- ORDレコード
- ord-49df807a707541b29b8c7e7fd0c9622e
- 出典データセット
- uspto-grants-2016_09
- 特許番号
- US09440982B2
関連ノート
読み込み中…